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currently being tested using Rev M10, a mutant form of the 
transdominant form of Rev. 
Both cell-mediated and direct gene transfer have been used in 
the optimization of gene therapies for vascular diseases, n Ceil- 
mediated gene transfer isan ex vivo procedure in which the vector 
is introduced into endothelial orsmooth muscle cells that have been 
harvested from an artery or vein and are maintained in cell culture. 
These cells are then delivered through acatheter into prespecified 
areas of an artery, where they establish t emselves. Investigations of 
vector delivery using replication-defective adenoviral vectors and 
DNA llposome complexes have been undertaken. The transfection 
efficiency provided by adenoviruses is higher than that obtained 
through other methods, but it is not yet known whether this 
expression elicits the desired reaction without causing toxicities. 
Improved nonviral vectors uch as DNA liposome complexes may 
provide an alternative approach. Recently, an adenoviral vector 
expressing herpesvirus thymidine ldnase was introduced invivo into 
bailoonqnjured porcine arteries. These cells responded to treat- 
ment with the nucleoside analog, ganciclovir, decreasing intimal 
hyperplasia) 2 Additional studies are now being conducted to 
optimize the vectors and delivery system. Several other gene 
products that arget cell proliferation, angiogenesis, or contractility 
have also shown promise in different animal models. 
Much progress has been made in understanding the role of 
specific genes in the pathogenesis of human disease. Gene therapy 
is now being tested in clinical studies for diverse medical problems. 
There is significant potential for this area of research to impact on 
both the understanding and treatment of a variety of human 
diseases. 
Gary Nabel, MD, PhD 
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University of Michigan 
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ANIMAL MODELS OF  D ISEASE 
L IP ID  D ISORDERS AND ATHEROSCLEROSIS  
IN  GENET ICALLY  MODIF IED MICE  
It is now generally accepted that he lesions ofatherosderosis begin 
as a result of some form of insult to the lining endothelial and 
smooth muscle cells of the artery wall. This insult can relatively 
rapidly lead to the development of a specialized, chronic inflam- 
matory response, characterized bythe presence of peripheral blood 
monocytes and T lymphocytes. In individuals with hyperiipidemia, 
transport of lipoproteins by the endothelial cells from the plasma 
into the artery wall may result in modification of some of these 
lipoproteins and, in part, to their oxidation. These modified 
lipoproteins may,-in turn, injure the overlying endothelial cells, 
resulting in continuing adherence ofmonocytes and T lymphocytes 
and to the development of chemotactic factors within the artery 
wall that draw these leukocytes between lining endothelial cells into 
the subjacent intima. 
Studies in human beings, nonhuman primates, rabbits, swine, 
and, most recently, hyperlipidemic, transgeulc ApoE-deficient mice 
demonstrate that one of the earliest observable changes within the 
artery is the increased adherence ofmonocytes and T lymphocytes 
to the endothellmn. These cells adhere to the endotheiium in 
clusters that appear to be localized throughout the arterial tree. 
Many of these adherent leukocytes are attached to the endothelium 
at sites of flow alteration, such as branches and bifurcations, as well 
as at the flow dividers within various parts of the artery. Before the 
appearance ofthese adherent leukocytes, particulate matter can be 
seen in the region between the endothellum and its underlying 
basement membrane. This particulate matter has the appearance of 
membranous whorls, as well as of lipoprotein particles, and has 
been described as liposome-like material. Thus there is evidence 
from human surgical and autopsy material and from specimens of 
experimental animals that monocyte and T lymphocyte adherence 
is preceded by the deposition of lipoid material beneath the 
endothelial cells. This lipoid material may somehow induce the 
formation of specific cell-surface adhesive glycoproteins on the 
surface of the endothelium, which could then lead to binding and 
attachment ofmonocytes and T ceils. 
The chemotactic attraction of these leukocytes into the artery 
leads to their localization subjacent to the endothelium and to the 
conversion of ma W of the subendothelial monocytes into mac- 
rophages or scavenger cells. These macrophages can actively bind 
and internalize the modified (oxidized) lipoproteins that may be 
present within the intimal space, become lipid laden, and take on 
the appearance of foam cells. Foam cell formation may lead to 
activation of the macrophages and to expression of genes for a series 
ofcytokines and growth-regulatory molecules. Cytoldnes that may 
be expressed by the macrophages include interleukin-1 (IL-1) and 
tumor necrosis factor (TNF), whereas the T lymphocytes may 
cxpress the gene'for interferon (IFN). In addition to the formation 
ofcytoldnes, the macrophages have the capacity to express genes for 
platelet-derived growth factors A and B (PDGF-A and PDGF-B), 
insulin-like growth factor 1 (IGF-1), hepatin-binding EGF-like 
growth factor (HB-EGF), and transforming rowth factor [3 
(TGF[3), as well as numerous others. The expression of these genes 
usually leads to their translation and, ultimately, to the possible 
secretion of these growth factors. Smooth muscle cells in the 
subjacent media of the artery wall contain receptors for PDGF, 
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making them possible, if not likely, targets for this growth factor. 
Because many of these cytoldnes and growth factors are potent 
chemoattractants for smooth muscle, particularly PDGF, many of 
the smooth muscle cells may be chemotactically attracted to 
migrate from the media into the intima. This could result from the 
formation of chemotactic factors, such as PDGF-BB, by the foam 
cells and possibly by the overlying endothelial cells. 
Thus a series of cellular interactions among monocyte-derived 
macrophages, T lymphocytes, overlying endothelial ceils, and 
subjacent smooth muscle cells can lead to the migration and intimal 
localization ofmacrophages and smooth muscle cells, which then 
can go on to replicate as a result of the presence of numerous 
growth-stimulatory molecules, uch as monocyte-colony sthnulat- 
ing factor (M-CSF), PDGF, and ItB-EGF. Furthermore, the 
release of cytokines, such as IL-1 and TNF, and other growth- 
regulatory molecules, uch as TGF[3, could lead to gene expression 
on the part of the smooth muscle cells of additional PDGF. The 
presence of TGF~ and its exposure to the smooth muscle cells could 
lead to stimulation of formation of connective tissue matrix 
constituents, including proteoglycans, collagen, and elastic fiber 
proteins by the smooth muscle cells within the neoinrima. Thus the 
net result of the different cellular interactions and the genes 
expressed by these cells could lead to a macrophage-smooth muscle 
fibroproliferative r sponse characteristic of those observed with 
long-term atherogenesis. 
ApoE-deficient mice 
Apolipoprotein (Apo).E-deficient transgenic mice develop 
severe hypercholesterolemia due to delayed clearance of large 
atherogenic particles from the circulation. These animals will 
develop lesions of atherosclerosis on a chow diet and accelerated 
lesions on a Western-type high fat diet. Lesions of atherosclerosis 
develop similarly to those described in human beings and most 
experimental animal models. Adhesion molecules, including 
ICAM-1 and VCAM-1, form at sites of low shear and high 
turbulence throughout the arterial tree, such as at branches and 
bifurcations. ICAM- 1 is normally present at these sites in wild-type 
animals, as well as in ApoE-deficient mice, but becomes up- 
regulated at the same sites in the ApoE-deficient mice. VCAM-1, 
on the other hand, appears with hypercholesterolemia coincident 
with the attachment of mononuclear ceils at these same sites. They 
enter into the artery wall, take up the lipid within the wall, and 
become foam cells, establishing fatty streaks at these sites. In older 
animals the same sites contain internaediate or advanced lesions, 
such as fibrous plaques and complicated lesions. The complicated 
lesions contain fibrous caps covering anecrotic ore and all of the 
cell types observed in human lesions in the same relative positions. 
Occlusive lesions of coronary arteries have been found, although to 
date no infarcts were observed, but  myocardial fibrosis has been 
noted. These animals thus represent a small murine model of 
atherogenesis that demonstrates many similarities with the human 
condition that should prove valuable in probing the process of 
atherogenesis and in testing approaches to treatment and preven- 
tion of this disease process. 
Response to injury and excess in a 
protective response 
Thus observations in experimentally-induced atherosclerosis 
and during various aspects of the progression ofthis disease support 
the response-to-injury hypothesis ofatherosclerosis that some form 
of damage (subtle or otherwise) to the endothelium leads to a series 
of cellular interactions that culminate in the process of atherogen- 
esis. The initial inflammatory process that is succeeded by migration 
and proliferation of lnonocytes and smooth muscle cells involves 
the establishment of a network of communication among the 
monocytes, mooth muscle cells, and the T lymphocytes that may 
be present in the lesions. Gene expression by each of these cell types 
will depend on local factors present within the microenvironment 
and will determine which stimulatory or inhibitory growth-regu- 
latory molecules and cytokines will be formed by these interacting 
cells. All of these vents appear to be associated with some form of 
injury and wound repair in a specialized tissue, such as the artery. 
Under most circumstances, if the injury and repair were optimal, 
the healing events would be followed by a somewhat s rengthened 
artery with no thickening of the artery wall. If, on the other hand, 
the injury is chronic and prolonged, as would be the case in 
individuals with chronic hyperlipidemia, hypertension, diabetes, 
cigarette smoking, or combinations of these risk factors, then it is 
conceivable that the injury-repair phenomenon may become x- 
cessive with time, leading to thickening of the wall, to alterations 
within the artery that could lead to localized thrombosis, and 
ultimately to occlusive lesions ofatherosclerosis. There is increasing 
evidence that the inflammation that may occur at the shoulders of 
the progressing, enlarged lesions of atherosclerosis may be sites in 
the artery that may be most susceptible to injury and thus subject 
to platelet interactions, mural thrombosis, and even fissuring or 
ulceration of the lesions that could lead to the formation of 
occlusive thrombi. Thus, in all of these respects, what may begin as 
a protective, inflammatory response may become an excessive 
response that ultimately becomes a disease process itself. 
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TRANSPLANTATION ATHEROSCLEROSIS :  
INS IGHT FROM ANIMAL MODELS 
The development of an accelerated form of arteriosclerosis cur- 
rently limits the long-term survival of solid organ allografts in 
humans. Various animal preparations permit study of the patho- 
genesis of transplantation arteriosclerosis. In general, these models 
combine allogeneic transplantation f a vascularized graft with 
manipulations that limit acute rejection (e.g., selection of weakly- 
reactive strain combinations or pharmacologic mmunosuppres- 
sion). This approach recapitulates lements of human transplanta- 
tion that produce transplantation arteriosclerosis. Rabbits and rats 
are convenient animals for technical reasons. Studies from our 
laboratory and many others have used these preparations to gain 
insight into the pathogenesis of graft vascular disease. 1,2 Despite 
their utility, the inability to alter conveniently the genetic make-up 
of these species has limited this type of experiment. Incomplete 
genetic characterization, relative lack of species-appropriate re- 
agents, and the paucity or absence of congenic strains further 
restrict he experiments possible with these species. For example, 
the lack of inbred strains in rabbits precludes isograft controls, 
which could permit he investigation ofnonimmune injury, (e.g., 
related to graft ischemia before implantation). 
Mouse models, although technically more challenging, offer 
unique opportunities toexamine mechanisms because of the wealth 
of knowledge and reagents related to mouse immunology and 
immunogenetics and the emerging availability of genetically altered 
strains of mice that will permit critical testing of hypotheses in vivo. 
Two mouse transplant models that appear useful are the hetero- 
topic heart ransplants (cervical or abdominal) and arterial inter- 
